Skip to main content
OpenTrials
Completed

NCT Number: NCT01699087

A Safety and Effectiveness Study of PRK Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System

The purpose of this study is to evaluate the safety and effectiveness of the ALLEGRETTO WAVE EYE-Q excimer laser system for the reduction of myopia with or without astigmatism in subjects undergoing photorefractive keratectomy (PRK) treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myopia Astigmatism Eye Diseases Refractive Errors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This was a prospective, multi-center, single group study. Subjects underwent bilateral PRK in which the second eye was treated no sooner than 1 week and no later than 30 days after the first eye's PRK treatment. Subjects were followed for 2 years after surgery.

The protocol underwent 4 amendments. The key differences between the protocol versions were clarifications of the planned analyses and adverse event reporting procedures. There were no changes in the inclusion and exclusion criteria or non-adverse event related study assessments between the protocol versions 1-5.

Refractive stability of manifest refraction spherical equivalent (MRSE) and manifest refractive cylinder was defined as established when:

  • At least 95% of the treated eyes had a change ≤ 1.0 diopter between manifest refractions performed at any 2 manifest refractions at least 3 months apart
  • The mean rate of change, as determined by a paired analysis, was ≤ 0.5 diopter per year (0.04 D/month) over the same time period
  • The mean rate of change decreased monotonically over time, with a projected asymptote of zero or a rate of change attributable to normal aging
  • The 95% confidence interval for the mean rate of change included zero or a rate of change attributable to normal aging.

Refractive stability was assessed for pairs of visits within an interval and was defined to occur at the latter time point of the first interval at which stability was achieved.

In the final amendment to the protocol, 3 secondary objectives were made co-primary in response to Agency comments. All endpoints and analyses were modified to match.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects desiring refractive correction of myopia up to -6.00 Diopter (D) sphere with or without astigmatism 0 to -3.00 D and up to -6.00 D manifest refraction spherical equivalent (MRSE) at the spectacle plane measured by manifest refraction;
  • Minimum best spectacle corrected visual acuity (BSCVA) in the treated eye of 20/25;
  • Uncorrected visual acuity (UCVA) 20/40 or worse in the treated eye;
  • Less than 0.75 D spherical equivalent (SE) difference between cycloplegic and manifest refractions;
  • Stable refraction (within ± 0.5 D), as determined by MRSE for a minimum of 12 months prior to surgery;
  • Demonstrated stable refraction for contact lens wearers, as specified in protocol;
  • Signed informed consent document;
  • Willing and able to comply with schedule for follow-up visits;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Females who are pregnant, lactating, or planning a pregnancy during the time course of the study, or have another condition associated with the fluctuation of hormones that could lead to refractive changes;
  • Participation in other clinical trials during this study;
  • Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study;
  • Dry eye syndrome as determined by the short questionnaire for dry eye syndrome;
  • Systemic medications that may confound the outcome of the study or increase the risk to the subject by affecting wound healing or tissue repair, including, but not limited to steroids, antimetabolites, immune response modifying drugs, etc.;
  • Nystagmus or any other condition that would prevent a steady gaze during the PRK treatment or other diagnostic tests;
  • Ocular condition that may predispose the subject to future complications;
  • Previous intraocular or corneal surgery;
  • Subjects who desire to have monovision;
  • A known sensitivity to medications used for study procedures, including PRK;
  • Presence or history of any condition or finding that makes the subject unsuitable as a candidate for PRK or study participation or may confound the outcome of the study, in the opinion of the Investigator;
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

Photorefractive keratectomy (PRK)

Procedure

In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.

ALLEGRETTO WAVE EYE-Q excimer laser system

Device

The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery

Other names: ALLEGRETTO WAVE Eye-Q, WaveLight® EX500, WaveNet™ Planning Software, ALLEGRETTO WAVE® EYE-Q excimer laser system (Model 1010-3)

Primary outcomes

  1. Percentage of Eyes Achieving Uncorrected Visual Acuity (UCVA) of 20/40 or Better at Refractive Stability in Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) of 20/20 or Better Preoperatively

    Time frame: Month 6 (post second eye surgery)

    Visual acuity, with and without correction, was assessed monocularly using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 4 meters under photopic conditions . The with-correction assessment was made with the manifest refraction at 4 meters.

  2. Percentage of Eyes Achieving Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.0 D of Zero at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Manifest refraction spherical equivalent (MRSE) is calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  3. Percentage of Eyes Achieving MRSE Within ± 0.5 D of Zero at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Manifest refraction spherical equivalent (MRSE) is calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  4. Percentage of Eyes Achieving Manifest Refractive Cylinder Within ± 1.0 D of Zero at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter.

  5. Percentage of Eyes Achieving Manifest Refractive Cylinder Within ± 0.5 D of Zero at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter.

  6. Percentage of Eyes That Have a Change of ≤ 1.0 D in MRSE and Manifest Refractive Cylinder Between Consecutive Scheduled Visits

    Time frame: Up to Month 24 (post second eye surgery)

    MRSE is calculated as sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  7. Cumulative Incidence of Ocular Serious Adverse Events by Eye

    Time frame: Up to Month 24 (post second eye surgery)

    Participants were followed for the duration of the study, an expected average of 24 months.

  8. Percentage of Eyes With BSCVA Decrease of ≥ 2 Lines From Baseline at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Visual acuity with correction was assessed monocularly using the ETDRS chart at 4 meters under photopic conditions . A decrease in 2 lines or more is considered clinically relevant (i.e. worse).

  9. Percentage of Eyes With a BSCVA Worse Than 20/40 (for Eyes With BSCVA of 20/20 or Better Preoperatively) at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Visual acuity with correction was assessed monocularly using the ETDRS chart at 4 meters under photopic conditions .

  10. Percentage of Eyes With > 2.0 D of Induced Manifest Refractive Cylinder Magnitude, as Compared to Baseline, at Refractive Stability

    Time frame: Month 6 (post second eye surgery)

    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter. The cylinder value is from the manifest refraction assessment. The induced manifest refractive cylinder is the change in magnitude of cylinder compared to baseline.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Prospective Safety and Effectiveness Study of PRK for Myopia With or Without Astigmatism Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Oct 3, 2012
Registry last updated
Sep 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.